Skip to main content
Research news

New international medical code launches for presymptomatic type 1 diabetes

JDRF-funded researchers from the University of Birmingham have joined forces with NHS England to develop a diagnostic code for use on electronic medical records of people in the earliest stages of type 1 diabetes, allowing them to receive better, more timely healthcare and access to emerging treatments.
Content last reviewed and updated: 13.05.2024

A female doctor works at a laptop on a table. She is wearing a shirt and glasses with a stethoscope around her neck.

A new code for presymptomatic type 1 diabetes has today been added to SNOMED CT, a standardised, international, multilingual set of clinical healthcare terminology. SNOMED codes are added to electronic health records to identify what conditions a person has. It is the most comprehensive and precise clinical health terminology system in the world.

Type 1 develops in stages

Type 1 diabetes develops gradually, and this progression occurs in three stages, with the first two stages called presymptomatic type 1 diabetes. People with presymptomatic type 1 diabetes have biological markers of type 1 diabetes, known as autoantibodies, which show the immune attack that destroys insulin-producing beta cells has begun. As the symptoms of type 1 are not present at this stage, we rely on screening programmes such as the ELSA study, which are funded by charities like JDRF, for early detection.

Transforming type 1 diabetes research

Dr Lauren Quinn at the University of Birmingham, who co-leads the ELSA study and helped develop the new medical code, said: “The introduction of this SNOMED code allows researchers to identify people who could benefit from novel therapies to delay the onset of type 1 diabetes and recruit them to clinical trials of immunotherapies. This will transform type 1 diabetes research by fast-tracking recruitment, unravelling how the condition develops and progresses, and bringing us closer to licensed disease-modifying treatments in type 1 diabetes.”

Better monitoring and diagnosis

Dr David Shukla, a GP and Clinical Research Fellow who helped develop the new SNOMED code, said: “The inclusion of a code for the diagnosis of presymptomatic type 1 diabetes will highlight to healthcare professionals involved in their care the individuals who are at high risk of developing type 1 diabetes. This will help ensure that when these people progress and develop symptomatic type 1 diabetes, it will be picked up and treated at a much earlier stage.

This reduces the risk of them presenting or being diagnosed late and developing diabetic ketoacidosis, an emergency complication of type 1 diabetes that can be fatal. This timely pick up and initiation of prompt treatment will lead to substantial improvements in their diabetes and future care.”

A vital step for early detection

Hilary Nathan, Director of Policy and Communications at JDRF UK, said: “This recognition of presymptomatic type 1 diabetes with a SNOMED code is a crucial step towards the implementation of population screening programmes for early detection of type 1 diabetes. Early detection leads to short and long-term health benefits, improved quality of life and cost savings for healthcare providers.

The new code will unlock better monitoring, follow-up and education for people in the earliest stages of type 1. It will also help facilitate recruitment into clinical trials of emerging treatments, enabling people developing type 1 diabetes to access therapies that have the potential to claw back valuable time free from the burdens of type 1 diabetes management.”

More research news

Read more
A row of vials of clear liquid with black lids. A blue gloved hand is pinching the top of the closest vial as if to pick it up.
13 May 2024

Novel insulin being developed to enable implantable insulin pumps

Medtronic Diabetes have announced they are funding the biopharmaceutical company Arecor Therapeutics to develop a novel, highly concentrated, thermostable insulin, which will be specialised for use in implantable insulin pumps.

Read more
Professor Colin Dayan at Cardiff University, working on immunotherapy for type 1 diabetes cure research
18 April 2024

Professor Colin Dayan presented with the 2023 JDRF Rumbough Award 

The award recognises Professor Dayan’s remarkable accomplishments in type 1 diabetes research.

Read more
Two young children sat on the floor hugging each other.
18 April 2024

Genetically unique siblings reveal new treatment target for type 1 diabetes

Two siblings who have unique changes in a key gene have given researchers new insights that could help lead to innovative new treatments in type 1 diabetes.

Read more
Professor Richard Oram in the Research, Innovation, Learning and Development (RILD) building at the University of Exeter.
7 March 2024

New biochip launches that detects genetic risk of type 1 diabetes

A new test by Randox, developed with JDRF-funded researchers at the University of Exeter, is the first in the world to use genetics to quickly identify who is at high risk of developing type 1 diabetes.